(Q38940292)

English

NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Pengfei Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Liang Ye

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Hongbo Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Guangying Du

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jianzhao Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jinghai Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jingwei Tian

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

publication date

15 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

2143-2153

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Design, synthesis and antiproliferative activity of novel 2-substituted-4-amino-6-halogenquinolines

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Geldanamycin and its anti-cancer activities

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Targeting mTOR signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2824-X

21 January 2018

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398692

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Counteracting the activation of pAkt by inhibition of MEK/Erk inhibition reduces actin disruption-mediated apoptosis in PTEN-null PC3M prostate cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398692

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398692

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on options for treatment of metastatic castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398692

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398692

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of mitogen-activated protein kinase associated with prostate cancer progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398692

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13277-014-2824-X

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38940292&oldid=2202334073"